Cameron Lionel Groome, CEO and Director, acquired 333,334 Common Shares on a direct ownership basis at a price of $0.300 through a prospectus or prospectus exempt offering on October 18th, 2017. The insider also acquired 166,668 Warrants with an exercise price of $0.360 for 3 years. This represents a $100,000 investment into the company's shares and an account share holdings change of greater than 100%.
On the same terms, James Stuart Currie, CFO, acquired 50,000 Common Shares and 25,000 Warrants on a direct ownership basis. This represents a $15,000 investment into the company's shares and an account share holdings change of greater than 100%.
Microbix Biosystems is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.
Microbix Biosystems Inc. is a life science company and manufacturer of viral and bacterial antigens and reagents for the diagnostics industry. The Company develops biological products and technologies. The Company operates in two segments: the development, manufacturing and distribution of cell-based products and technology, and the provision of facility, technical and production personnel for contract research and development. The Company's Virology Products (Virology) business manufactures and sells cell culture-based biological products. The Company's pipeline of technologies and products include Kinlytic, which is a thrombolytic drug with various applications, including the treatment of life-threatening blood clots, and LumiSort, which is a semen sexing technology for the livestock industries. It operates in three geographical areas, including North America, Europe and in other foreign countries. It owns and operates a Virology manufacturing facility at Mississauga, Ontario.
No Comments